Mortality Rates in Malignant Meningiomas and Stratification by Age at Diagnosis, Race, and Sex: A Ten-Year Population Based Observational Study

Poster #2574

Simo Kraguljac, Chris S. Karas MD
Disclosures

- I have read the AANS/NREF/NPA Corporate Guidelines and understand that my decisions as an AANS/NREF/NPA Board, Committee Member, speaker, content planner or Staff must conform to this policy.

- I have read the AANS/NREF/NPA Conflict of Interest Policy and understand that my decisions as an AANS/NREF/NPA Board, Committee Member, speaker, content planner or Staff must conform to this policy.

- I have read the AANS Non-Discrimination, Anti-Retaliation, and Harassment Policy and understand that as an AANS/NREF/NPA Board, Committee Member, speaker, content planner or Staff, I need to be aware of this policy and will report any perceived violations to the AANS Executive Director or to AANS/NREF/NPA legal counsel.

- I have read the AANS Policy Regarding Harassment and Disruptive Behavior at Meetings and Courses and understand that as an AANS/NREF/NPA Board, Committee Member, speaker, content planner or Staff, I need to be aware of this policy and will report any perceived violations to the AANS Executive Director or to AANS/NREF/NPA legal counsel.

- CME Conflict for Education: I have read and I understand and agree with the statements above.

- I DO NOT have any financial or organizational relationships with commercial interests or other entities. I hereby certify that to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having a conflict of interest with my duties, responsibilities and exercise of independent judgement as an Officer, Member of the Board of Directors, Nominee for Office, Educational Presenter and/or a representative of AANS/NREF/NPA.

- Personal Information Consent: I have read and understood the information above. I consent to the AANS retaining personal information about me and using such information to send emails and other communications to me. I further consent to the AANS sharing my personal information with its third-party vendors, when necessary.

- Recording Release: I consent

- Final Statement Response: I agree
Introduction

Meningiomas are the most common benign brain tumor in adults. Depending on location, the approach to the management, treatment and natural history of benign meningiomas is well established. Less is known regarding the natural history and optimal treatment of malignant meningiomas.
Methods

We reviewed meningioma data from the National Cancer Institute & Surveillance Epidemiology and End Results (SEER) database. We reviewed patients with known ages at diagnosis and only malignant cases between 2000 and 2010, as defined by SEER. 12- and 60-month survival data was analyzed by sex, age, and race.
Results – Age at Diagnosis

• 1098 cases in this study

• Typically older patients: 661 patients 60+ years old, 12 patients 0-19 years old
Results - Race

- Majority of patients were white: 726 cases, no other race had more than 172 cases
- Black patients had the highest 12- and 60-month mortality rates.
Results - Sex

- Female patients account for 60.7% of cases
- Males have higher 12- and 60-month mortality rates
Discussion

• The majority of malignant meningiomas are found in older populations and are more common in females

• Gender and race seem to correlate with differing mortality rates

• Identifying these trends will allow for advancement in treatment and counseling for meningioma patients
Summary Points

• Statistics regarding malignant meningiomas are not well known at this point

• This study provides possible trends that can allow for better treatment and counseling for malignant meningiomas

• More studies are needed to examine genetic and biochemical factors that affect these differing mortality rates